ALPHA IVF GROUP BERHAD
202101005100 (1405399-X)

ALPHA IVF GROUP BERHAD
AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE FOURTH QUARTER ENDED 31 MAY 2026

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FOURTH QUARTER ENDED 31 MAY 2026

	Note	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
		31.5.2026 RM'000	31.5.2025 RM'000	31.5.2026 RM'000	31.5.2025 RM'000
Revenue	A9	**52,071**	**50,007**	**198,588**	**176,842**
Cost of sales		(20,666)	(19,371)	(79,624)	(69,686)
Gross profit		**31,405**	**30,636**	**118,964**	**107,156**
Other income		1,191	1,601	5,948	6,421
Administrative expenses		(11,803)	(8,939)	(43,114)	(33,060)
Other expenses		(1,144)	(1,539)	(6,338)	(3,294)
Finance costs		(215)	(387)	(1,602)	(1,084)
Profit before taxation ("PBT")	B12	**19,434**	**21,372**	**73,858**	**76,139**
Income tax expense	B6	(5,564)	(5,120)	(20,613)	(17,575)
Profit after taxation ("PAT")		**13,870**	**16,252**	**53,245**	**58,564**
Other comprehensive income					
Item that will be reclassified subsequently to profit or loss					
Foreign currency translation differences		(1,984)	(342)	(5,434)	(856)
Total comprehensive income		11,886	15,910	47,811	57,708
Profit after taxation attributable to:					
Owners of the Company		13,900	16,068	53,635	57,454
Non-controlling interests		(30)	184	(390)	1,110
		13,870	16,252	53,245	58,564
Total comprehensive income attributable to:					
Owners of the Company		12,075	15,741	48,843	56,706
Non-controlling interests		(189)	169	(1,032)	1,002
		11,886	15,910	47,811	57,708
Earnings per share attributable to Owners of the Company					
Basic/Diluted (sen)(1)	B11	0.29	0.33	1.10	1.18

Note:
(1) The basic and diluted earnings per share of the Company are computed based on PAT attributable to the Owners of the Company divided by the weighted average number of ordinary shares outstanding during the period, excluding treasury shares of the Company referred to in Note B11. The Group has not issued any dilutive potential ordinary shares and hence, the diluted earnings per share is equal to the basic earnings per share.

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MAY 2026

	Unaudited As at 31.5.2026 RM'000	Audited As at 31.5.2025 RM'000
ASSETS		
Non-Current Assets		
Equipment	35,928	13,767
Right-of-use assets	39,649	22,425
Other investments	20,303	30,563
Goodwill	8,931	8,931
Deferred tax assets	1,493	1,702
	106,304	77,388
Current Assets		
Inventories	3,611	2,817
Trade receivables	2,068	1,590
Other receivables, deposits and prepayments	8,648	13,127
Current tax asset	-	5
Short-term investments	97,258	121,449
Cash and bank balances	37,009	34,432
	148,594	173,420
TOTAL ASSETS	254,898	250,808
EQUITY AND LIABILITIES		
Share capital	119,753	119,753
Treasury shares	(5,570)	-
Retained profits	58,037	55,971
Reorganisation reserve	22,499	22,499
Foreign exchange translation reserve	(4,977)	(185)
Equity attributable to Owners of the Company	189,742	198,038
Non-controlling interests	5,885	6,109
Total Equity	195,627	204,147
Non-Current Liabilities		
Lease liabilities	30,355	21,659
Provision for restoration costs	1,264	1,227
	31,619	22,886
Current Liabilities		
Trade payables	1,016	2,808
Other payables and accruals	10,119	5,701
Contract liabilities	8,018	8,329
Lease liabilities	3,347	1,848
Current tax liabilities	5,152	5,089
	27,652	23,775
Total Liabilities	59,271	46,661
TOTAL EQUITY AND LIABILITIES	254,898	250,808
Net assets per ordinary share attributable to Owners of the Company (RM)	0.04	0.04

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FOURTH QUARTER ENDED 31 MAY 2026

	Share Capital	Treasury shares	Reorganisation Reserve	Foreign Exchange Translation Reserve	Retained Profits	Attributable to Owners of the Company	Non-Controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
As at 1 June 2025	119,753	-	22,499	(185)	55,971	198,038	6,109	204,147
Profit after taxation for the financial period	-	-	-	-	53,635	53,635	(390)	53,245
Other comprehensive expenses for the financial period:								
- Foreign currency translation differences	-	-	-	(4,792)	-	(4,792)	(642)	(5,434)
Total comprehensive (expenses)/income for the financial period	-	-	-	(4,792)	53,635	48,843	(1,032)	47,811
Repurchase of treasury shares of the Company	-	(5,570)	-	-	-	(5,570)	-	(5,570)
Dividend by the Company	-	-	-	-	(48,515)	(48,515)	-	(48,515)
Acquisition of additional interests in a subsidiary	-	-	-	-	(3,054)	(3,054)	(2,722)	(5,776)
Ordinary share capital contributed by non-controlling interests	-	-	-	-	-	-	3,530	3,530
As at 31 May 2026	119,753	(5,570)	22,499	(4,977)	58,037	189,742	5,885	195,627

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FOURTH QUARTER ENDED 31 MAY 2026

	Period Ended 31.5.2026 RM'000	Period Ended 31.5.2025 RM'000
CASH FLOW FROM OPERATING ACTIVITIES		
Profit before taxation	73,858	76,139
Adjustments for:		
Depreciation of equipment	5,428	2,554
Depreciation of right-of-use assets	4,588	3,237
Interest expenses	1,602	1,084
Equipment written off	64	20
Gain on disposal of equipment	(20)	(70)
Gain on disposal of investment	(29)	-
Gain on termination of lease	(1)	#
Fair value gain on unit trust funds	(122)	-
Dividend income from a short-term investment	(8)	-
Unrealised loss on foreign exchange	663	503
Interest income	(4,159)	(5,566)
Operating profit before working capital changes	81,864	77,901
Changes in working capital:		
Inventories	(826)	97
Trade and other receivables	4,044	(6,561)
Trade and other payables	2,470	(527)
Contract liabilities	(277)	1,583
CASH FROM OPERATIONS	87,275	72,493
Income tax paid	(20,544)	(17,580)
NET CASH FROM OPERATING ACTIVITIES	66,731	54,913
CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of additional interest in a subsidiary	(5,776)	-
Proceed from disposal of equipment	20	70
Proceed from disposal of investment	10,130	-
Dividend income from a short-term investment	8	-
Interest income	3,843	5,566
Purchase of equipment	(27,268)	(7,321)
Additional right-of-use assets	(418)	-
Withdrawal of short-term investments	24,785	32,120
NET CASH FROM INVESTING ACTIVITIES	5,324	30,435
CASH FLOW FOR FINANCING ACTIVITIES		
Dividend paid by the Company	(48,515)	(46,170)
Repurchase of own shares	(5,570)	-
Proceeds from issuance of share capital to non-controlling interests	3,530	2,830
Interest paid	(1,566)	(714)
Repayment of lease liabilities	(11,894)	(3,328)
NET CASH FOR FINANCING ACTIVITIES	(64,015)	(47,382)
Net increase in cash and cash equivalents	8,040	37,966
Effect of foreign exchange translation	(4,593)	(1,288)
Cash and cash equivalents at beginning of the financial period	59,584	22,906
Cash and cash equivalents at end of the financial period	63,031	59,584
Note:		
Cash and cash equivalents comprise of the following:		
Short-term investments - money market funds	26,022	25,152
Cash and bank balances	37,009	34,432
	63,031	59,584

– Less than RM1,000.

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 31 MAY 2026

A1. Basis of Preparation

The interim financial report of Alpha IVF Group Berhad ("Company") and its subsidiaries ("Group") are unaudited and have been prepared in accordance with requirements of Malaysian Financial Reporting Standards ("MFRS") No. 134: Interim Financial Reporting and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 as disclosed in the Annual Report 2025 and the accompanying notes attached to this interim financial report.

A2. Summary of Significant Accounting Policies

The significant accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted in the most recent audited annual financial statements for the year ended 31 May 2025. During the current financial period, the Group has adopted the following new accounting standards and/or interpretations (including the consequential amendments, if any):

MFRSs and/or IC Interpretations (Including the Consequential Amendments)	Effective Date
Amendments to MFRS 121: Lack of Exchangeability	1 January 2025

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) did not have any material impact on the Group's financial statements.

The Group has not applied in advance the following accounting standards and/or interpretations (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standard Board ("MASB") but are not yet effective for the financial period ended 31 May 2026:

MFRSs and/or IC Interpretations (Including the Consequential Amendments)	Effective Date
Annual Improvements to MFRS Accounting Standards – Volume 11	1 January 2026
Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and Measurement of Financial Instruments	1 January 2026
Amendments to MFRS 9 and MFRS 7: Contracts Referencing Nature-dependent Electricity	1 January 2026
MFRS 18: Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19: Subsidiaries without Public Accountability: Disclosures	1 January 2027
MFRS 121: Translation to a Hyperinflationary Presentation Currency	1 January 2027
Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred

The Group is in process of assessing the impact of implementing the above accounting standards and/or interpretations in the year of initial application.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 31 MAY 2026 (CONT'D)

A3. Auditors' Report on preceding Annual Financial Statements

There was no qualification on the audited consolidated financial statements of the Group for the financial year ended 31 May 2025.

A4. Seasonal or cyclical factors

The business operation of the Group has not been materially affected by any unusual seasonal or cyclical factors.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and financial period-to-date.

A6. Material changes in estimates

There were no material changes in estimates that have a material effect to the Group in the current financial quarter and financial period-to-date.

A7. Debt and equity securities

As at 31 May 2026, the Company had repurchased and held a cumulative total of 20,415,600 of its issued ordinary shares as treasury shares in accordance with Section 127 of the Companies Act 2016. After deducting these treasury shares, the number of ordinary shares in circulation stood at 4,839,584,400.

Other than the above, there were no issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the current financial quarter under review.

A8. Dividends Paid

The Company had declared a second single-tier interim dividend of 0.50 sen per ordinary share amounting to RM24,300,000, on 28 July 2025, in respect of the financial year ended 31 May 2025. The dividend was paid on 29 August 2025 and the entitlement date was on 11 August 2025.

The Company had declared a first single-tier interim dividend of 0.50 sen per ordinary share amounting to RM24,214,655.91, on 22 January 2026, in respect of the financial year ending 31 May 2026. The dividend was paid on 31 March 2026 and the entitlement date was on 19 March 2026.

The total dividend of RM48,514,655.91 declared and paid has been accounted for in equity as an appropriation of retained earnings for the financial year ending 31 May 2026.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 31 MAY 2026 (CONT'D)

A9. Segmental Reporting

The Group operates predominantly in one business segment i.e. focused only in the business of operating women's specialists centres and provision of assisted reproductive, Obstetrics and Gynaecology services. Accordingly, the information by business segments is not presented.

Geographical Market

The following table provides an analysis of the Group's revenue by geographical segment:

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	31.5.2026	31.5.2025	31.5.2026	31.5.2025
	RM'000	RM'000	RM'000	RM'000
Revenue				
- Malaysia	45,369	46,446	178,772	157,156
- Singapore	4,577	3,511	16,089	19,636
- Indonesia	591	50	1,753	50
- Philippines	1,534	-	1,974	-
	52,071	50,007	198,588	176,842

A10. Valuation of Equipment

There was no valuation of equipment in the current financial quarter under review.

A11. Material events subsequent to the end of the current financial quarter

There are no material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

A12. Changes in the composition of the Group

Save as disclosed below, there were no changes in the composition of the Group during the current financial quarter under review.

(a) Increase of issued and paid-up capital of Alpha IVF System Sdn. Bhd. ("AIS")

On 17 March 2026, AIS, a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM35,200,000 to RM39,200,000 by the issuance of 4,000,000 new ordinary shares. The Company subscribed for the additional 4,000,000 ordinary shares at RM1 each.

(b) Increase of issued and paid-up capital of Alpha IVF (China) Incorporation ("AIIC")

On 3 April 2026, AIIC, a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM2,000,000 to RM3,100,000 by issuance of an aggregate of 1,100,000 new ordinary shares. The Company subscribed for the additional 1,100,000 ordinary shares at RM1 each.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 31 MAY 2026 (CONT'D)

A12. Changes in the composition of the Group (Cont'd)

(c) Increase of issued and paid-up capital of PT Alpha SPOG Indonesia ("PT SPOG")

On 7 May 2026, PT SPOG, an indirect subsidiary of the Company, increased its issued and paid-up capital from RM2,837,624 to RM5,780,510 through the issuance of 1,070,707 new ordinary shares at Indonesian Rupiah ("IDR") 10,000.00 (approximately RM2.75) per ordinary share. AIS and AIWS, both wholly-owned subsidiaries of the Company, collectively subscribed for the 1,070,707 new ordinary shares at RM2.75 each.

A13. Contingent Assets and Contingent Liabilities

There were no contingent assets and contingent liabilities as at the date of this interim financial report.

A14. Material capital commitments

Save as disclosed below, there is no material commitment for capital expenditure, which upon becoming enforceable, may have a material effect on the Group's financial position as at the date of this interim financial report.

	31.5.2026	31.5.2025
	RM'000	RM'000
Purchase of equipment	24,390	12,615

(THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK)

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 31 MAY 2026 (CONT'D)

A15. Significant related party transactions

The Group carried out the following significant transactions with related parties during the financial period:

Transacting Parties	Nature of transaction	CURRENT QUARTER ENDED 31.05.2026 RM'000	CURRENT QUARTER ENDED 31.05.2025 RM'000	CUMULATIVE PERIOD ENDED 31.05.2026 RM'000	CUMULATIVE PERIOD ENDED 31.05.2025 RM'000
Significant transactions with Directors of the Company					
(i) AIWS and Dato' Dr. Lee Soon Soo ("DDLSS")	Consultancy services provided by DDLSS	(358)	(321)	(1,359)	(1,247)
(ii) Genesis and Dr. Ng Peng Wah ("DNPW")	Consultancy services provided by DNPW	(720)	(736)	(2,836)	(2,797)
Significant transactions with Directors of the Subsidiaries					
(iii) AIWS and Dr. Haris Bin Hamzah ("Dr. Haris")	Consultancy services provided by Dr. Haris	(49)	(72)	(214)	(229)
(iv) Alhaya and Dr. Haris	Consultancy services provided by Dr. Haris	(43)	(45)	(164)	(230)
Significant transactions with Related Parties					
(v) AIWSS and Dr. Tan Heng Hao ("Dr. Tan")	Consultancy services provided by Dr. Tan	(5)	(28)	(58)	(3,082)
(vi) AIWSS and Dr. Tan	Administrative fee income charged to Dr. Tan	-	-	-	43
(vii) AIWS and Baby Xort Sdn. Bhd. ("Baby Xort")	Sperm sorting services provided by Baby Xort	(6)	(188)	(360)	(640)
(viii) Alhaya and Baby Xort	Sperm sorting services provided by Baby Xort	-	-	(7)	(7)

AIWS – Alpha International Women's Specialists Sdn. Bhd.
AIWSS – Alpha International Women's Specialists (Singapore) Pte. Ltd.
Genesis – Genesis Specialists Sdn. Bhd.
Alhaya – Alhaya International Women's Specialists Sdn. Bhd.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

B1. Review of Performance

(a) Results for current quarter

For the financial quarter ended 31 May 2026, the Group recorded a revenue of RM52.07 million, representing an increase of RM2.06 million or 4.12% as compared to RM50.01 million in the preceding year corresponding quarter ended 31 May 2025. The increase in revenue is due to higher sales from Singapore and the new Philippines centre. The Group's revenue was principally derived from the provision of assisted reproductive services.

The Group recorded a PBT of RM19.43 million and PAT of RM13.87 million for the current financial quarter as compared to a PBT of RM21.37 million and PAT of RM16.25 million for the preceding year corresponding quarter ended 31 May 2025. The decrease in PBT by RM1.94 million or 9.07% and PAT by RM2.38 million or 14.65% was primarily due to pre-operational costs related to the Group's ongoing expansion initiatives.

(b) Results for financial period-to-date

For the financial period ended 31 May 2026, the Group recorded a revenue of RM198.59 million, representing an increase of RM21.75 million or 12.30% as compared to RM176.84 million in the preceding corresponding period ended 31 May 2025. The increase was primarily attributable to higher sales from local and foreign patients in the Malaysian centres. The Group's revenue continued to be principally derived from the provision of assisted reproductive services.

The Group recorded a PBT of RM73.86 million and PAT of RM53.25 million for the current financial period, representing a decrease of RM2.28 million or 2.99% in PBT and RM5.31 million or 9.07% in PAT as compared to the preceding corresponding period ended 31 May 2025. The lower PBT and PAT were primarily due to increased pre-operational costs related to the Group's ongoing expansion initiatives.

B2. Comparison with immediate preceding quarter's results

On a quarter-on-quarter basis, the Group recorded revenue of RM52.07 million, representing an increase of RM4.95 million or 10.51% compared to RM47.12 million in the immediate preceding quarter ended 28 February 2026. The increase in revenue was mainly attributable to higher sales from Malaysian and Philippines centres during the current quarter under review.

The Group recorded a PBT of RM19.43 million and PAT of RM13.87 million in the current financial quarter ended 31 May 2026, representing an increase of RM2.46 million or 14.50% in PBT and RM1.71 million or 14.06% in PAT compared to the immediate preceding quarter ended 28 February 2026, which recorded a PBT of RM16.97 million and PAT of RM12.16 million. The increase in PBT and PAT were primarily due to increase in revenue.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B3. Prospects

The structural drivers supporting demand for Assisted Reproductive Services ("ARS") — including delayed parenthood and declining fertility rates — remain firmly in place. With its ongoing expansion initiatives now entering the next phase of execution, the Group is transitioning from a period of heavy setup investment toward one of operational scaling and revenue generation.

The Group's newest IVF centres in Sabah and Manila, both operational since December 2025, are progressing through their initial ramp-up phase. Patient intake has been encouraging, and both centres are on track to achieve higher utilisation rates as they become more established in their respective markets. Additionally, the Group's satellite clinics in Medan and Surabaya, which have been operational for some time, continue to provide an increasing number of patient referrals to the Group's IVF centres in Malaysia, further strengthening the cross-border patient flow within the region.

The Group made significant progress on its development pipeline during the quarter, bringing several projects closer to revenue-generating status. In Malaysia, renovation works for the Johor centre commenced in July 2026, with the centre now targeted to open by the end of 2026. Internationally, the Group's expansion continues across the region: the Tuguegarao centre in the Philippines and the Jakarta centre in Indonesia are both on track for a 1H FY2027 launch, while the Bali centre in Indonesia is progressing towards mid 2027 operational date.

As these new centres move closer to opening, the Group expects the associated pre-operating expenses to gradually taper off. This positions the Group to benefit from a broader earnings base as new centres open and mature, expecting to contribute incrementally to the Group's financial performance in FY2027 and beyond.

With a growing footprint across Malaysia, Indonesia, Singapore, the Philippines, and China, the Group is building a resilient and diversified regional platform. As these centres scale and new ones come online, the Group is confident in its ability to deliver sustained long-term growth and reinforce its position as a trusted leader in fertility care across Asia.

B4. Profit forecast or profit guarantee

The Group did not issue any profit forecast or profit guarantee in any public document in respect of the interim financial reporting period under review.

B5. Status of corporate proposals

There were no corporate proposals announced but not completed as at the date of this interim financial report.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B6. Income tax expense

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	31.5.2026	31.5.2025	31.5.2026	31.5.2025
	RM'000	RM'000	RM'000	RM'000
Income tax expense				
- Current year	4,831	4,901	19,869	17,741
- Prior year	410	(57)	421	(440)
Deferred tax expense				
- Current year	323	186	323	184
- Prior year	-	90	-	90
	5,564	5,120	20,613	17,575
Effective tax rate (%)	29%	24%	28%	23%

The Group's effective tax rate for the current quarter and financial period ended 31 May 2026 was higher than the statutory tax rate of 24%, mainly due to under provision of tax expenses in prior year.

(THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK)

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B7. Utilisation of Proceeds from the Initial Public Offering ("IPO")

The gross proceeds raised from the Public Issue is RM116.64 million and the status of the utilisation of proceeds as at 31 May 2026 is as follows:

Details of utilisation	Initial	After variations (1)	Utilised as at 31 May 2026	Unutilised IPO Proceeds	Timeframe for utilisation
	RM'000	RM'000	RM'000	RM'000	
Establishing new medical centres, satellite clinics and sales representative offices as follows:-					
(a) Two (2) specialist centres in Malaysia	32,000	21,400	(12,141)	9,259	
(b) Two (2) specialist centres in Indonesia	17,100	17,100	(4,956)	12,144	
(c) Four (4) satellite clinics in Indonesia	7,000	6,200	(5,327)	873	
(d) One (1) specialist centre in Laos / Cambodia	13,900	-	-	-	
(e) Two (2) sales representative offices in China	2,800	2,400	(1,921)	479	Within 36 months from the listing date
Expansion and upgrade of existing medical centres, facilities and corporate office	15,700	13,670	(6,982)	6,688	Within 36 months from the listing date
Establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China	-	27,500	(18,793)	8,707	Within 36 months from 21 August 2024
Research and development	2,200	2,200	(2,200)	-	Within 36 months from the listing date
General working capital	17,140	17,370	(11,722)	5,648	Within 36 months from the listing date
General corporate purposes	2,600	2,600	(1,877)	723	Within 36 months from the listing date
Defraying the listing expenses	6,200	6,200	(6,200) (2)	-	Within 1 month from the listing date
Total	116,640	116,640	(72,119)	44,521	

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B7. Utilisation of Proceeds from the IPO (Cont'd)

The utilisation of proceeds as disclosed above should be read in conjunction with the Prospectus dated 1 March 2024 in relation to its IPO and the announcement on variations of utilisation of IPO proceeds dated 21 August 2024.

Notes:

(1) The Company had varied the utilisation of IPO Proceeds to reallocate a total of RM27.73 million or approximately 23.77% for (i) establishing new medical centres, satellite clinics and sales representative offices and (ii) expansion and upgrade of existing medical centres, facilities and corporate office to (i) establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China as well as (ii) general working capital.

(2) The listing expenses of RM5.89 million have been fully paid and the balance of RM0.31 million will be used as working capital of the Group. The Company has since fully utilised the RM0.31 million for working capital purpose.

B8. Group Borrowings and Debt Securities

There were no group borrowings and debt securities as at 31 May 2026 and 31 May 2025.

B9. Material Litigation

There was no material litigation involving the Group as at 31 May 2026.

B10. Dividend Proposed or Declared

The Company declared a second single-tier interim dividend of 0.60 sen per ordinary share on 4,837,084,400 shares in respect of the financial year ended 31 May 2026 amounting to RM29,022,506.40, which is payable on 14 October 2026 to shareholders whose names appear in the Company's Register of Members and/or Record of Depositors on 30 September 2026.

B11. Earnings per share

The basic earnings per share ("EPS") is calculated by dividing the profit for the period attributable to Owners of the Company by weighted average number of ordinary shares (excluding treasury shares) of the Company during the financial period as follows:

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	31.5.2026	31.5.2025	31.5.2026	31.5.2025
Profit attributable to Owners of the Company (RM'000)	13,900	16,068	53,635	57,454
Weighted average number of ordinary shares (excluding treasury shares) ('000)	4,843,347	4,860,000	4,855,933	4,860,000
Basic/Diluted EPS (sen)	0.29	0.33	1.10	1.18

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)

B12. Notes to the Condensed Statement of Profit or Loss and Other Comprehensive Income

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	31.5.2026	31.5.2025	31.5.2026	31.5.2025
	RM'000	RM'000	RM'000	RM'000
Profit before taxation is arrived at after charging/(crediting):				
Depreciation of equipment	1,739	716	5,428	2,554
Depreciation of right-of-use assets	1,232	985	4,588	3,237
Fair value gain on short-term investments:				
- money market funds	(199)	-	(817)	-
- unit trust funds	(24)	-	(122)	-
Dividend income from a short-term investment	(2)	-	(8)	-
Interest income	(770)	(1,264)	(4,159)	(5,566)
Interest expenses	215	387	1,602	1,084
Equipment written off	2	20	64	20
Gain on disposal of equipment	-	-	(20)	(70)
Gain on disposal of investment	(29)	-	(29)	-
(Gain)/Loss on termination of lease	-	#	(1)	#
Unrealised (gain)/loss in foreign exchange	(404)	503	663	503
Realised (gain)/loss in foreign exchange	238	35	17	(2)

Note
- Less than RM1,000.

B13. Approval of Interim Financial Report

The interim financial report as set out above was authorised for issuance by the Board of Directors on 23 July 2026.